Skip to content

Genitalia and Androgen in New Born Girls

Study Protocol: Reference Values for External Genitalia and Androgen Blood Level in New Born Girls

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02826278
Acronym
VOGE
Enrollment
180
Registered
2016-07-07
Start date
2014-10-31
Completion date
2016-08-31
Last updated
2016-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newborn Genitalia

Keywords

Newborn genitalia, reference charts

Brief summary

Normal values for female external genitalia size at birth, particularly clitoris and blood level of androgens are not well known. This study's aim is to collect normal values in 180 newborn girls of 24 to 41 weeks of pregnancy, and to build genitalia growth charts according to gestational age and birth weight. The investigators will measure clitoris, genito-anal ratio using a small plastic caliper, at birth, and their evolution until Day 3 of life (if the child is still at the hospital). The investigators also want to establish normal values of blood testosterone, 17-hydroxyprogesterone, delta4-androstenedione, 21-deoxycortisol, 11-deoxycortisol, deoxycorticosterone, corticosterone, dehydroepiandrostenedione, and dihydrotestosterone), using samples taken for systematic post natal screening of diseases (only in new born of 35 or more weeks of birth). This is an observational prospective study.

Interventions

OTHERExternal genitalia measurements in female newborns

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 3 Days
Healthy volunteers
Yes

Inclusion criteria

* Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances. Dysmature children - i.e. those with a - 2DS birth weight or height at are not excluded.

Exclusion criteria

* Sexual development abnormality, diagnosed pre- or post- birth, endocrine disorder, obstetric trauma affecting genitalia, malformation syndrome, midline abnormalities, congenital cancer, maternal ovary or adrenal tumor diagnosed during pregnancy, mother or father's treatment during pregnancy likely to virilize the fetus, family history of congenital adrenal hyperplasia or neurofibromatosis

Design outcomes

Primary

MeasureTime frameDescription
length of the clitorisDay 1The measurement is performed on the supine child, with flexed hips and knees retained by the nurse or the nursery nurse. The clitoris will be delimited using cavernosa palpation. The clitoris length will be measured from maxima lablias'root to the top of clitoris, excluding cutaneous cover. Measurements are performed using an-8 cm plastic caliper.

Secondary

MeasureTime frameDescription
anogenital ratioDay 1The ano-genital ratio is the ratio between 1) the distance from anus center to the base of clitoris and 2) the distance from anus center and the posterior commissure of the vulva frenulum.
Blood level of testosteroneDay 3This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
Blood level of 17-hydroxyprogesteroneDay 3This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
clitoris widthDay 1The clitoris will be measured at its base, using an-8 cm plastic caliper.
Blood level of 21-deoxycortisolDay 3This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
Blood level of corticosteroneDay 3This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
Blood level of dihydrotestosteroneDay 3This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA
Blood level of delta4-androstenedioneDay 3This dosage will be performed using a 1.5 ml blood sample taken for screening purpose (for routine systematic post natal screening) only in newborn over 35 WA

Countries

France

Contacts

Primary ContactClaire-Lise GAY, MD
claire-lise.gay@chu-lyon.fr472 129 531
Backup ContactCornu Catherine, MD
catherine.cornu@chu-lyon.fr472 357 231

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026